Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy (First Line Therapy, Second Line Therapy), By Route of Administration (Oral, Parenteral, Others), By Dosage Form (Tablets, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharm
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationTuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy (First Line Therapy, Second Line Therapy), By Route of Administration (Oral, Parenteral, Others), By Dosage Form (Tablets, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharm
According to the World Health Organization (WHO), TB is one of the top 10 causes of death worldwide, with an estimated 10 million people falling ill with the disease in 2019.
According to the WHO, over 90% of TB cases occur in developing countries, where access to proper healthcare and diagnostic tools is limited.
Additionally, global population is aging, and older adults are more susceptible to TB due to age-related declines in immune function. As the population continues to age, the demand for TB therapeutics that are safe and effective in older adults is expected to increase, thereby driving the growth of global tuberculosis therapeutics market.
Increasing Instances of Drug Resistance
Tuberculosis is caused by a bacterium that can mutate rapidly, leading to drug-resistant strains that are difficult to treat. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are two forms of drug-resistant TB that pose a significant challenge to global health. The emergence of drug-resistant strains of TB has increased the demand for novel TB therapeutics that can effectively treat these difficult-to-treat strains. This in turn is expected to increase the demand for novel therapeutics that can address the issue of drug resistance related to tuberculosis, thereby fuelling the growth of global tuberculosis therapeutics market in the coming years. In the past decade, several new TB drugs have been developed, including bedaquiline, delamanid, and pretomanid. Bedaquiline is a novel drug that has been shown to be effective against drug-resistant TB, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Delamanid has also been shown to be effective against drug-resistant TB, particularly when used in combination with other TB drugs. Pretomanid, the newest of the three drugs, has been approved for the treatment of extensively drug-resistant TB.
Advancements in Tuberculosis Diagnostics
Advances in diagnostic tools have also improved the treatment of TB. One example is the use of Xpert MTB/RIF, a rapid molecular diagnostic test that can detect TB and drug resistance in just two hours. Another diagnostic tool is the GeneXpert Omni, which can detect TB and drug resistance in less than 90 minutes. These tools can help clinicians make more accurate diagnoses and choose the most appropriate treatment regimen for their patients. The development in diagnostic methods for tuberculosis is leading to the development of effective therapeutic solutions as well, thereby opening new prospects for the growth of global tuberculosis therapeutics market in the coming years.
Use of Combination Therapies
The use of combination therapies in the treatment of various chronic and infectious diseases has increased over the years significantly opening new opportunities for the growth and development of novel therapeutics. The use of combination therapies is becoming increasingly common in the treatment of TB. Combination therapies involve the use of multiple drugs to treat TB, which can improve treatment outcomes and reduce the risk of drug resistance. One example of a combination therapy is the use of bedaquiline and delamanid in the treatment of MDR-TB. Another combination therapy, called the BPaMZ regimen, uses the drugs bedaquiline, pretomanid, moxifloxacin, and pyrazinamide to treat drug-sensitive TB. The use of combination therapies in the treatment of tuberculosis is expected to drive the growth of global tuberculosis therapeutics market in the coming years.
Increased Research and Development Activities
According to clinicaltrials.gov, there are around 1,092 studies in different phases of development across the globe for developing a treatment for combating tuberculosis.
Additionally, studies are going on to find effective treatments with shorter regimens. Traditionally, TB treatment has involved a long course of antibiotics that can last for up to two years. However, recent research has shown that shorter treatment regimens may be just as effective. One example is the use of the BPaL regimen, which uses the drugs bedaquiline, pretomanid, and linezolid to treat drug-resistant TB. This regimen has been shown to be effective in treating TB in as little as six months. This in turn is expected to support the growth of global tuberculosis therapeutics market in the coming years.
In addition to these new drugs and regimens, researchers are also exploring the potential of repurposing existing drugs for the treatment of TB. For example, a study published in the journal Science in 2020 found that a drug called niclosamide, which is currently used to treat intestinal infections, showed promising results in killing Mycobacterium tuberculosis in laboratory experiments. The researchers are now planning to conduct clinical trials to test niclosamide's effectiveness in treating TB in humans. This is further expected to open new prospects for the growth of global tuberculosis therapeutics market in the coming years.
Growing Prevalence of HIV
According to WHO, as of 2021, there are around 38.4 million people living with HIV worldwide.
Market Segmentation
Global Tuberculosis Therapeutics Market can be segmented by disease type, by therapy, by route of administration, by dosage form, by distribution channel, and by region. Based on disease type, global tuberculosis therapeutics market can be split into active tuberculosis and latent tuberculosis. By therapy, the global tuberculosis therapeutics market can be divided into first line therapy and second line therapy. Based on route of administration, the global tuberculosis therapeutics can be categorized into oral, parenteral, and others. By dosage form, the global tuberculosis therapeutics market can be segmented into tablets, capsules, injection, and others. In terms of distribution channel, the global tuberculosis therapeutics market can be grouped into hospital pharmacy, retail pharmacy, and online pharmacy. Regionally, the global tuberculosis therapeutics market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
Market Players
AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., among others are some of the leading players operating in the global Tuberculosis Therapeutics market.
Recent Developments
In 2019, Otsuka Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for a new TB drug, Pretomanid, for the treatment of extensively drug-resistant TB.
GlaxoSmithKline (GSK), which has a TB drug development program focused on developing drugs that are effective against drug-resistant TB. GSK is currently testing a drug called GSK3036656 in clinical trials, which has shown promise in early studies.
In 2019, the US Food and Drug Administration (FDA) approved a new drug called pretomanid. Pretomanid is part of a three-drug regimen called BPaL, which also includes bedaquiline and linezolid, that has been shown to be highly effective in treating highly drug-resistant forms of TB. In a phase III trial conducted in South Africa, the BPaL regimen cured 90% of patients with extensively drug-resistant TB, a form of TB that is resistant to at least four of the main TB drugs. The BPaL regimen is also shorter than the previous standard of care for drug-resistant TB, taking just six months instead of up to two years.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | By Disease Type By Therapy By Route of Administration By Dosage Form By Distribution Channel By Region |
| Regional scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
| Key companies profiled | AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy